Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 8 | 2025 | 341 | 1.790 |
Why?
|
| Pancreatectomy | 2 | 2025 | 101 | 1.070 |
Why?
|
| Liver Neoplasms | 3 | 2025 | 297 | 0.960 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2025 | 8 | 0.950 |
Why?
|
| Pancreatic Fistula | 1 | 2024 | 18 | 0.890 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2025 | 178 | 0.810 |
Why?
|
| Surgical Flaps | 1 | 2024 | 117 | 0.800 |
Why?
|
| Robotic Surgical Procedures | 1 | 2024 | 161 | 0.710 |
Why?
|
| Postoperative Complications | 3 | 2024 | 1308 | 0.670 |
Why?
|
| Pyrimidinones | 3 | 2016 | 16 | 0.670 |
Why?
|
| Pyridones | 3 | 2016 | 40 | 0.650 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 217 | 0.400 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 238 | 0.380 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 864 | 0.320 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 663 | 0.320 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2016 | 111 | 0.240 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2025 | 19 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2016 | 188 | 0.230 |
Why?
|
| ErbB Receptors | 2 | 2014 | 114 | 0.200 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 348 | 0.200 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 770 | 0.170 |
Why?
|
| Middle Aged | 5 | 2025 | 17613 | 0.160 |
Why?
|
| Male | 6 | 2025 | 29891 | 0.150 |
Why?
|
| Caregivers | 1 | 2021 | 272 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 190 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 2 | 2014 | 56 | 0.130 |
Why?
|
| Humans | 11 | 2025 | 63449 | 0.130 |
Why?
|
| Mutation | 2 | 2014 | 2612 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6658 | 0.120 |
Why?
|
| Hemangioma | 1 | 2015 | 28 | 0.120 |
Why?
|
| Adenoma | 1 | 2015 | 70 | 0.120 |
Why?
|
| Hepatectomy | 1 | 2015 | 63 | 0.120 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2015 | 64 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2014 | 936 | 0.110 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 24 | 0.110 |
Why?
|
| Trastuzumab | 1 | 2014 | 17 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 70 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2014 | 69 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2014 | 31 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2014 | 54 | 0.110 |
Why?
|
| Quinazolines | 1 | 2013 | 22 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 207 | 0.100 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 1469 | 0.100 |
Why?
|
| Aged | 4 | 2024 | 14447 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 465 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 345 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 525 | 0.090 |
Why?
|
| Genomics | 1 | 2014 | 370 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 507 | 0.080 |
Why?
|
| Neoplasms | 1 | 2021 | 1364 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2014 | 3035 | 0.080 |
Why?
|
| Adult | 2 | 2024 | 16824 | 0.080 |
Why?
|
| Female | 4 | 2024 | 32881 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2187 | 0.070 |
Why?
|
| Animals | 3 | 2016 | 20659 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 322 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 719 | 0.040 |
Why?
|
| Prognosis | 2 | 2014 | 1748 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2021 | 152 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 393 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2021 | 519 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 3293 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 690 | 0.030 |
Why?
|
| Cystadenoma | 1 | 2015 | 7 | 0.030 |
Why?
|
| Virginia | 1 | 2015 | 25 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 456 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 113 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 2172 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2014 | 26 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 92 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 88 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 207 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2014 | 226 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 278 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 373 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 374 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 297 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 583 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 167 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 509 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2013 | 82 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 226 | 0.020 |
Why?
|
| Mice | 2 | 2016 | 10844 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1654 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2570 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2458 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 5462 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 4694 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2015 | 5680 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 6245 | 0.010 |
Why?
|